T-DXd with brain radiation for HER2+ breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75 years with breast cancer that has spread to the brain.
- Your cancer must be HER2-positive or HER2-low (we can check with your doctor).
- You must be able to take care of most daily activities (ECOG score 0-2).
- You have not had radiation to the brain or treatment with T-DXd before.
- Your heart, blood, and other organs are working well enough (your doctor will test this).
- You do not have serious lung disease, uncontrolled infections, or other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies, Trastuzumab Deruxtecan (T-DXd) and Pyrotinib, as a first treatment for HER2-positive breast cancer that has spread or cannot be removed. It aims to see if this combination works better than standard treatments.
This trial tests a combination of a targeted drug (T-DXd) and precise radiation (stereotactic radiotherapy) for people with HER2-positive breast cancer that has spread to the brain. The goal is to see if this approach can better control brain tumors.
This trial tests how well an imaging test can predict the effectiveness of the drug T-DXd in people with HER2-positive breast cancer that has spread to the brain. It aims to see if a special scan can help guide treatment.
This trial tests a new way of giving the targeted drug T-DXd—directly into the fluid around your spine (intrathecal) or through a device under your scalp called an Ommaya reservoir. It's designed for people with HER2-positive breast cancer that has spread to the brain or the lining of the brain/spinal cord.
This study looks at how safe and effective the drug T-DXd (trastuzumab deruxtecan) is for Chinese patients with a specific type of lung cancer that has a HER2 mutation. It helps understand if this treatment works well in real-world settings.
This trial tests a drug called T-DXd in people with advanced non-squamous lung cancer that has a specific HER2 gene change (mutation) and has spread to the brain but isn't causing symptoms. The goal is to see if the drug can shrink tumors and help control the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.